Share: 
Status: 
Active
Rating: 
No votes yet
0

Advanced Therapeutics to Address Patient-Specific Disease Activity in Multiple Sclerosis

Course description

This CME program will give physicians insight into the ever-growing research in the field of multiple sclerosis. The faculty review MS treatment guidelines and recommendations, including recently updated phenotype descriptions. The experts break down the therapeutic needs in relapsing and progressive MS and analyze novel therapeutics. Emerging therapies are discussed in order to give physicians the most up-to-date information on their options when treating their MS patients. The faculty will guide the learners on creating a personalized approach when developing treatment plans. All these factors will enable physicians to create the best path forward for their current and future MS patients.

TARGET AUDIENCE

This activity has been designed to meet the educational needs of neurologists, and other healthcare professionals responsible for the diagnosis, treatment or management of patients with multiple sclerosis.

EDUCATIONAL OBJECTIVES

Upon completion of this activity, participants will be better able to:

  1. Discuss patient assessment guidelines and recommendations for the treatment of multiple sclerosis such as MRI imaging techniques and monitoring disease activity.
  2. Describe the mechanisms of action of available and emerging therapies for the treatment of multiple sclerosis, and their effects of relapse, MRI lesions, and progression.
  3. Formulate individualized treatment plans to effectively align disease activity and therapeutic selection to optimize outcomes in patients with multiple sclerosis.

FACULTY

Clyde E. Markowitz, MD
Director, MS Center
Associate Professor, Department of Neurology
University of Pennsylvania, Perelman School of Medicine
Philadelphia, Pennsylvania

Mark Freedman, MD
Professor of Medicine
University of Ottawa
Senior Scientist
Ottawa Hospital Research Institute Ottawa
Ontario, Canada

Andrew Goodman, MD
Professor of Neurology
Chief of the Neuroimmunology Unit
Director of the Multiple Sclerosis Center
University of Rochester
Rochester, New York

Disclosure of Conflicts of Interest

It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity. 

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

FacultyRelationship Identified With:

Clyde E. Markowitz, MD

Consultant/Advisor: Acordia; Bayer AG; Biogen Idec, Inc.; EMD Serono, Inc.; F. Hoffmann-La Roche Ltd.; Genentech Inc.; Novartis Pharmaceuticals Corporation; ONO Pharmaceutical Co., LTD.; sanofi-aventis US LLC; Teva Phamaceutical Inducstries

Mark Freedman, MD

Consultant/Advisor: Actelion Pharmaceuticals US, Inc.; Bayer AG; Biogen Idec, Inc.; Chugai Pharmaceutical Co., LTD.; EMD Serono Inc.; Genzyme Corporation; Opexa Therapeutics Inc.

Speaker's Bureau: Genzyme Corporation

Andrew Goodman, MD

Consultnat/Advisor: Acorda Therapeutics Inc.; Biogen IDEC; EMD Serono, Inc.; Genzyme Corporation, a Sanofi company; Novartis Pharmaceuticals Corporation; Teva Pharmaceutical Industries Ltd.

Grant/Research Support: Acorda Therapeutics Inc.; Avanir Pharmaceuticals, Inc.; Biogen IDEC; EMD Serono, Inc.; Genzyme Corporation, a Sanofi company; Novartis Pharmaceuticals Corporation; ONO PHARMACEUTICAL CO., LTD.; Roche Holding AG; Sun Pharmaceutical Industries Ltd.; Teva Pharmaceutical Industries Ltd.

Non-faculty: Sandy Breslow; Alison Kemp; Timothy Hayes, MD, PhD; Kristen Scollon; Emma Gilmartin; Nicole Brestowski; and Bernard M. Abrams, MD hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the last 12 months. 

Financial Support

This CME activity has been supported by an independent educational grant from Novartis Pharmaceuticals Corporation.

Provider Information

Co-provided by the Elsevier Office of Continuing Medical Education and AcademicCME.

CME Credit (Physicians)

The Elsevier Office of Continuing Medical Education is accredited by the Acceditation Council for Continuing Medical Education (ACCME) to provide continuing education for physicians.

The Elsevier Office of Continuing Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME INQUIRIES/SPECIAL NEEDS

For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.


Disclosure of Unlabeled Use This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Elsevier Office of Continuing Medical Education, AcademicCME, and Novartis Pharmaceuticals Corporation do not recommend the use of any agent outside of the labeled indications.

Disclaimer Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Credits & accreditation
  • 1.00 AMA PRA Category 1 Credit(s)™
  • 1.00 Non-physician
Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit(s)™
  • 1.00 Non-physician
Course opens: 
04/04/2016
Course expires: 
04/03/2017
Please login or register to take this course.